Last edition
News about Market
Harbour BioMed Signs Strategic Collaboration with Lannacheng on Radionuclide Drug Conjugates
Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation radionuclide drug conjugates, combining both companies’ resources and expertise to accelerate innovation in targeted radiopharmaceutical therapies.
Market | 30/12/2025 | By News Bureau
Aurobindo Pharma Extends Timeline for Acquisition of Stake in Swarnaakshu Solar Power
Aurobindo Pharma has announced that the completion of its captive solar power purchase agreement and the acquisition of up to a 26 percent stake in Swarnaakshu Solar Power has been deferred to March 31, 2026, due to pending state government approvals for setting up the solar power plant.
Market | 30/12/2025 | By News Bureau
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
Market | 30/12/2025 | By News Bureau
Under the agreement, Transcenta will grant EirGenix a non-exclusive licence to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages.
Market | 30/12/2025 | By News Bureau
ABL Bio Secures USD 40 Million Upfront, USD 15 Million Equity Investment From Eli Lilly
ABL Bio, a company focused on bispecific antibody technologies, announced that it will receive a USD 40 million upfront payment under a license, research, and collaboration agreement for its proprietary Grabody platform, along with a USD 15 million equity investment from Eli Lilly and Company.
Market | 29/12/2025 | By Darshana
ABL Bio Receives Upfront Payment and Equity Investment from Lilly for Grabody Platform
ABL Bio has secured a total of USD 55 million in funding from Lilly, including a USD 40 million upfront payment and a USD 15 million equity investment, under a license, research and collaboration agreement to advance R&D and expand indications for its Grabody platform.
Market | 26/12/2025 | By News Bureau
Windtree Therapeutics to Sell Cardiovascular Pipeline Assets
Windtree Therapeutics has agreed to sell its cardiovascular biotech pipeline assets to Seismic Pharmaceuticals under a deal that includes a potential USD 700,000 contingent payment, transfer of certain development payables, and Windtree retaining a 20 percent share of any future milestone, royalty, or global commercial revenue generated from the assets.
Market | 26/12/2025 | By News Bureau
Aurobindo Pharma to Increase Stake in China JV for USD 5.12 Million
Aurobindo Pharma has announced plans to increase its shareholding in its China-based joint venture, Luoxin Aurovitas Pharma (Chengdu), by 20 percent through a cash investment of USD 5.12 million.
Market | 26/12/2025 | By Darshana
Shionogi to Acquire Global Rights to RADICAVA ORS and IV RADICAVA
Shionogi plans to acquire the global rights and assets of Tanabe Pharma's RADICAVA ORS (edaravone) and IV RADICAVA, strengthening its rare disease portfolio, establishing a dedicated commercial platform in the U.S., and adding an estimated USD 700 million in annual global sales, with the transaction expected to be immediately accretive in FY26.
Market | 26/12/2025 | By News Bureau
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Sanofi has agreed to acquire Dynavax, strengthening its adult immunisation portfolio with an approved hepatitis B vaccine and a shingles vaccine candidate in phase I/II development. The deal combines Dynavax’s vaccine assets with Sanofi’s global development and commercial capabilities.
Market | 24/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy